Literature DB >> 10100315

Enantioselective synthesis and pharmacological evaluation of a new type of verapamil analog with hypotensive and calcium antagonist activities.

H L Holland1, J X Gu, F Orallo, M Camiña, P Fabeiro, A J Willetts.   

Abstract

PURPOSE: The syntheses and evaluation for cardiovascular activity in the rat of both enantiomers of a verapamil analog in which the cyano group has been replaced by hydroxyl.
METHODS: (+)- and (-)-alpha-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]methylamino]propyl]- 3,4-dimethoxy-alpha-(1-methyl ethyl)benzyl alcohol were prepared from chiral sulfoxides produced by microbial biotransformations using Mortierella isabellina ATCC 42613 or Helminthsporium species NRRL 4671, and were examined for hypotensive and calcium antagonist activity using anaesthetized normotensive rats and isolated rat aorta and atria.
RESULTS: The analogs showed a pharmacological profile similar to that exhibited by verapamil, possessing a remarkable hypotensive activity, accompanied by a significant bradycardia, in anaesthetized normotensive rats. In vitro, these analogs displayed clear inhibitory effects: in isolated rat aorta they inhibited, in a concentration-dependent fashion, the contractions and 45Ca2+ uptake induced by norepinephrine and high KCl, and in isolated rat atria the analogs considerably decreased the rate of contraction (negative chronotropic effects). No significant differences between the quantitative cardiovascular effects produced by the two enantiomers of the verapamil analogs were observed.
CONCLUSIONS: The results suggest that, like that of verapamil, the cardiovascular activity exhibited by the new compounds seems to be due, at least in part, to a blockage of transmembrane calcium channels present in vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100315     DOI: 10.1023/a:1018888711071

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  12 in total

1.  [(N-methyl-N-homoveratryl)-gamma-aminopropyl]-3,4-dimethoxyphenyl-acetonitrile, a substance with coronary vasodilating properties].

Authors:  H HAAS; G HAERTFELDER
Journal:  Arzneimittelforschung       Date:  1962-06

Review 2.  Do the K+ channel openers relax smooth muscle by opening K+ channels?

Authors:  U Quast
Journal:  Trends Pharmacol Sci       Date:  1993-09       Impact factor: 14.819

3.  Interaction between calcium and slow channel blocking drugs on atrial rate.

Authors:  M C Camilión de Hurtado; H E Cingolani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-02       Impact factor: 3.000

Review 4.  Regulation of cytosolic calcium levels in vascular smooth muscle.

Authors:  F Orallo
Journal:  Pharmacol Ther       Date:  1996       Impact factor: 12.310

5.  A search for calcium-channel activators in the verapamil series.

Authors:  M N Romanelli; F Gualtieri; R Mannhold; A Chiarini
Journal:  Farmaco       Date:  1989-05

6.  Study of the in vivo and in vitro cardiovascular effects of a hydralazine-like vasodilator agent (HPS-10) in normotensive rats.

Authors:  F Orallo
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

7.  Exaggerated hypotensive responses to calcium antagonists in spontaneously hypertensive rats.

Authors:  Y Takata; J S Hutchinson
Journal:  Clin Exp Hypertens A       Date:  1983

8.  Role of the endothelial system in Bay K 8644 enantiomer and nifedipine vasomodulator action in rat aorta.

Authors:  J Gil-Longo; F Orallo; I Verde; M Campos; J M Calleja
Journal:  Eur J Pharmacol       Date:  1992-10-06       Impact factor: 4.432

9.  A comparison of the effects of the calcium entry blockers, verapamil, diltiazem and flunarizine against contractions of the rat isolated aorta and portal vein.

Authors:  J F Marriott
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

10.  Effect of urethane on hydralazine-induced tachycardia in rats.

Authors:  F Orallo; J A Fontenla; M I Loza; M Campos; J M Calleja
Journal:  Gen Pharmacol       Date:  1992-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.